| Patient | Ida B. Wells |
|---|---|
| Date of birth | 1957-07-16 |
| Identifiers | MRN HR-ET022-SYN; SSN (made up) 000-22-5903 |
| Document date | 2026-01-05 |
| Author | Cordelia Ashworth-Banks, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
The patient attends this visit for new patient visit for tiredness and ankle swelling, with kidney function, urine albumin, blood count, and mineral and bone tests. [S]
Sodium: 139 mmol/L; Potassium: 4.6 mmol/L; Bicarbonate (total CO2): 22 mmol/L; Urea nitrogen: 28 mg/dL (high); Glucose (fasting): 94 mg/dL; Creatinine: 1.42 mg/dL (high); eGFR, creatinine (CKD-EPI 2021, race-free): 40 mL/min/1.73 m² (low); Cystatin C: 1.68 mg/L (high); eGFR, creatinine and cystatin C (CKD-EPI 2021, race-free): 38 mL/min/1.73 m² (low); Urine albumin-to-creatinine ratio: 240 mg/g (high); Hemoglobin A1c: 5.6%; Hemoglobin: 11.2 g/dL (low); Ferritin: 168 ng/mL; Transferrin saturation: 24%; Calcium: 9.2 mg/dL; Phosphate: 3.8 mg/dL; Parathyroid hormone, intact: 84 pg/mL (high); 25-hydroxyvitamin D: 17 ng/mL (low); Total cholesterol: 214 mg/dL (high); LDL cholesterol: 136 mg/dL (high); HDL cholesterol: 52 mg/dL; Triglycerides: 128 mg/dL; TSH: 1.9 mIU/L; PHQ-9: 4. [S]
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-01-05 | Body height | 157 | cm | S |
| 2026-01-05 | Body weight | 70.4 | kg | S |
| 2026-01-05 | Body mass index (BMI) [Ratio] | 28.6 | kg/m2 | S |
| 2026-01-05 | Systolic blood pressure | 164 | mm[Hg] | S |
| 2026-01-05 | Diastolic blood pressure | 94 | mm[Hg] | S |
| 2026-01-05 | Heart rate | 78 | /min | S |
| 2026-01-05 | Respiratory rate | 16 | /min | S |
| 2026-01-05 | Body temperature | 36.6 | Cel | S |
| 2026-01-05 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-01-05 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-01-05 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-01-05 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 22 | mmol/L | Keep at 22 or above in kidney disease | Normal | S |
| 2026-01-05 | Urea nitrogen [Mass/volume] in Serum or Plasma | 28 | mg/dL | 8-23 mg/dL | High | S |
| 2026-01-05 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-01-05 | Creatinine [Mass/volume] in Serum or Plasma | 1.42 | mg/dL | 0.59-1.04 mg/dL | High | S |
| 2026-01-05 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 40 | mL/min/{1.73_m2} | 60 or higher without other kidney damage markers; 45 to 59 is G3a, 30 to 44 is G3b, 15 to 29 is G4 | Low | S |
| 2026-01-05 | Cystatin C [Mass/volume] in Serum or Plasma | 1.68 | mg/L | 0.53-0.95 mg/L | High | S |
| 2026-01-05 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine and Cystatin C-based formula (CKD-EPI 2021)/1.73 sq M | 38 | mL/min/{1.73_m2} | The confirmatory estimate KDIGO prefers when decisions depend on accuracy; 30 to 44 is G3b | Low | S |
| 2026-01-05 | Albumin/Creatinine [Mass Ratio] in Urine | 240 | mg/g | Below 30 mg/g normal (A1); 30 to 300 moderately increased (A2); above 300 severely increased (A3) | High | S |
| 2026-01-05 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.6 | % | Below 5.7% is normal; 6.5% or higher is diabetes | Normal | S |
| 2026-01-05 | Hemoglobin [Mass/volume] in Blood | 11.2 | g/dL | Anemia in women is below 12.0 g/dL | Low | S |
| 2026-01-05 | Ferritin [Mass/volume] in Serum or Plasma | 168 | ng/mL | 30-300 ng/mL | Normal | S |
| 2026-01-05 | Iron saturation [Mass Fraction] in Serum or Plasma | 24 | % | 20-50% | Normal | S |
| 2026-01-05 | Calcium [Mass/volume] in Serum or Plasma | 9.2 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-01-05 | Phosphate [Mass/volume] in Serum or Plasma | 3.8 | mg/dL | 2.5-4.5 mg/dL | Normal | S |
| 2026-01-05 | Parathyrin.intact [Mass/volume] in Serum or Plasma | 84 | pg/mL | 15-65 pg/mL | High | S |
| 2026-01-05 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 17 | ng/mL | Below 20 ng/mL deficient; 20 to 29 insufficient | Low | S |
| 2026-01-05 | Cholesterol [Mass/volume] in Serum or Plasma | 214 | mg/dL | <=199 mg/dL | High | S |
| 2026-01-05 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 136 | mg/dL | <=99 mg/dL | High | S |
| 2026-01-05 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 52 | mg/dL | >=50 mg/dL | Normal | S |
| 2026-01-05 | Triglyceride [Mass/volume] in Serum or Plasma | 128 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-01-05 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 | m[IU]/L | 0.4-4.5 mIU/L | Normal | S |
| 2026-01-05 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, one or two tablets up to three times a day as needed for knee aching (no more than 3,000 mg a day), in place of naproxen | One or two tablets up to three times a day as needed | Oral route | 2026-01-05 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Tiredness for some months and ankle swelling by evening, with a raised creatinine (1.42 mg/dL, race-free eGFR 40, confirmed at 38 with cystatin C) and albumin in the urine (240 mg/g) found today; cause and chronicity to be established | active | confirmed | R94.4 | S — Synthetic presenting finding, superseded by the kidney diagnosis at two weeks. |
| Elevated blood pressure at intake (164/94 mmHg, average of two readings), without a diagnosis of hypertension; home readings for one week to confirm | active | confirmed | R03.0 | S — Synthetic presenting finding, superseded by the confirmed diagnosis at two weeks. |